A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer

By sjmartinez • August 25, 2023

Nguyen VP, Campbell KM, Nowicki TS, Elumalai N, Medina E, Baselga-Carretero I, DiNome ML, Chang HR, Oseguera DK, Ribas A, Glaspy JA. A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer. Cancer Res Commun. 2023 Aug 23;3(8):1628-1637. doi: 10.1158/2767-9764.CRC-23-0145. PMID: 37621406; PMCID: PMC10445661.

Tags: Hematology/Oncology, Publications

Patient-Reported Outcomes With Stereotactic Intensity Modulated Radiotherapy After Radical Prostatectomy: A Nonrandomized Clinical Trial

Nikitas J, Ballas LK, Romero T, Lynch C, Ma TM, Valle LF, Sachdeva A, Chong N, Basehart V, Franco A, Reiter R, Saigal C, Chamie[...]

Depression and Inflammation in Women with Breast Cancer: Risk and Resilience Factors

Korecki JRT, Slavich GM, Ganz PA, Irwin MR, Cole S, Crespi CM, Bower JE. Depression and Inflammation in Women with Breast Cancer: Risk and Resilience[...]

Somatic Tumor Next-Generation Sequencing in US Veterans With Metastatic Prostate Cancer

Valle LF, Li J, Desai H, Hausler R, Haroldsen C, Chatwal M, Ojo M, Kelley MJ, Rebbeck TR, Rose BS, Rettig MB, Nickols NG, Garraway[...]